Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 827 in Psoriatic Arthritis
NCT01516957Phase 2Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Oct 2011
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of brodalumab in psoriatic arthritis (PsA), sponsored by Valeant Pharmaceuticals. Started Oct 2011; status: terminated.
02
Drugs
brodalumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01516957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516957.